News

A new study sought to approach the HIV epidemic in the United States through a distributional cost-effectiveness analysis across 6 cities.

Fewer than 10,000 adverse events among more than 8.9 million doses administered.

The Centers for Disease Control and Prevention (CDC) endorses the additional COVID-19 vaccine shot in immunocompromised people.

A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.

"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."

Donald Alcendor, PhD, shares expert perspective on the newest FDA authorization, as well as what a full COVID-19 vaccine approval would mean for US immunization.

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

Three international trials combine data to find optimal heparin dosing against hypercoagulability and thrombosis in patients with COVID-19.

The Food and Drug Administration (FDA) is expected to expand the Emergency Use Authorization (EUA) of the Pfizer-BioNTech and Moderna vaccines for a third dose in those who might be vulnerable to COVID-19.

The vaccine demonstrated an acceptable safety profile in the adolescent population.

The federal agency recommends that all women who are pregnant, recently pregnant, and planning to become pregnant get the COVID-19 vaccine.

The cases include children and adults across four states.

Considering the care team members who need to help infectious disease specialists and pharmacists carry the stewardship torch.

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

The first case reported in Guinea has resulted in a patient's death, while health authorities work to reduce outbreak risks.

The active asthma group was not associated with a higher likelihood of mortality within 60 days.

Birth rates didn’t vary by whether the births were spontaneous or medically-indicated.

An expert from Temple reflects on the first 10 years of PrEP innovation, and what's needed in the next decade.

Drugs, personnel, and laboratory costs comprised 50%, 38%, and 12% of program costs.

A conversation with William Schaffner, MD.

A conversation with Anna Legreid Dopp, Pharm. D.

Fully vaccinated participants experienced an 80% reduction in symptomatic disease.

The study was the largest of its kind looking at the flu shot and COVID-19.

The severity and number of symptoms varied widely between individuals.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

Some patients who switched appear to have done so in anticipation of clinical indications.

Recent breakthrough infections have experts looking closely at the true risks of the COVID-19 delta variant and how we can protect ourselves.